New targeted therapies in the treatment of patients with metastatic melanoma;Nowe terapie celowane stosowane u chorych na czerniaka uogólnionego

Wspolczesna Onkologia

Volumn 14, Issue 1, 2010, Pages 15-22

  Mackiewicz, Jacek ^a,b   Kwinta, Łukasz ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b GREATER POLAND CANCER CENTRE   (Poland)

Author keywords

Chemotherapy; Kinase inhibitors; Melanoma; Monoclonal antibodies

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BMS 66353; CP 870 893; DACARBAZINE; DASATINIB; EVEROLIMUS; IMATINIB; INTETUMUMAB; IPILIMUMAB; MDX 1106; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OBLIMERSEN; PLX 4032; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TICILIMUMAB; TK 1258; UNCLASSIFIED DRUG; VOLOCIXIMAB;

CANCER INCIDENCE; CANCER SURVIVAL; CANCER THERAPY; DRUG TARGETING; HUMAN; HYPERTRIGLYCERIDEMIA; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; OVERALL SURVIVAL; POLAND; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77950409731     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: 10.5114/wo.2010.974     Document Type: Review

References (72)

1. Ruka W, Krzakowski M, Placek W i wsp. Czerniak skóry - zasady postȩpowania diagnostyczno-terapeutycznego. Onkol Prakt Klin 2009; 5: 20-32.
2. Hill GJ 2nd, Moss SE, Golomb FM, Grage TB, Fletcher WS, Minton JP, Krementy ET. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040. Cancer 1981; 47: 2556-2562
3. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomid versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
4. Aamadal S, Avril MD, Grob JJ, et al. A phase III randomized trial of fotemustine (F) versus dacarbazine (DTIC) in patients with disseminated malignant melanoma with or without brain metastases. Proc Am Soc Clin Oncol 2002; 21:136.
5. Einzig AI, Hochster H, Wiernik PH, et al. A Phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9: 59-64.
6. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A Phase II trial of taxol in metastatic melanoma. Cancer 1990; 65: 2478-2481
7. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232-1239
8. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 2002; 25: 283-286
9. Zimpfer-Rechner C, Hofmann U, Figl R, et al. Randomized Phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 2003; 13: 531-536
10. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy of metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19: 21-34.
11. Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999; 85: 1979-1984
12. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743-1751
13. Gibbs P, Iannucci A, Becker M, et al. A phase II study of biochemotherapy for metastatic malignant melanoma. Melanoma Res 2000; 10: 171-179
14. Philip PA, Flaherty LE. Biochemotherapy for melanoma. Curr Oncol Rep 2000; 2: 314-321
15. Wilczyńska B, Rolski J. Targeted therapy Part I. Signaling by tyrosine kinase receptor. Współcz Onkol 2007; 7: 331-336
16. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006; 407: 597-612.
17. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
18. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95: 581-586
19. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27: 2823-2830
20. Dummer R, Robert C, Chapman PB, et al. AZD6244 (ARRY-142886) vs. temozolomide in patients with advanced melanoma: an open label, randomized, multicenter, Phase II study. J Clin Oncol 2008; 26: Abstract 9033.
21. Chapman P, Puzanov I, Sosman J, et al. Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. ECCO-ESMO 2009; Abstract 6BA.
22. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64: 7002-7010
23. Rao RD, Windschitl H, Allred JB, et al. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol 2007; 24: 8043.
24. Kim KB, Davies MA, Papadopoulos NE, et al. Phase I/II study of combination of sorafenib and temsirolimus In patients with metastatic melanoma. ASCO 2009. Abstract 9026.
25. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26: 2046-2051
26. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematological and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109: 4143-4150
27. Carvajal RD, Chapman PB, Wolchok L, et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 2009; Abstract 9001.
28. Kluger HM, Dudek A, McCann C, et al. A phase II trial of dasatinib in advanced melanoma. J Clin Oncol 2009; Abstract 9010.
29. Docester L, Vande Broek I, Declerq D, et al. Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers. ECCO-ESMO 2009; Abstract O-9305.
30. Kim KB, Saro J, Moschos SS. A phase I dose Winding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma. J Clin Oncol 26: 2008; 20. Abstract 9026.
31. Fruehauf JP, Lutzky J, McDermott DF, et al. Axitinib (AG-013736) in patients with metastatic melanoma: a Phase II study. J Clin Oncol 2008; 26. Abstract 9006.
32. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003; 22: 3172-3179
33. Kurzen H, Schmitt S, Naher H, Mohler T. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 2003; 14: 515-522
34. Lacal PM, Failla CM, Pagani E, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 2000; 115: 1000-1007
35. Lev DC, Onn A, Melinkova VO, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004; 22: 2092-2100
36. Lev DC, Ruiz M, Mills L, et al. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2000; 32: 753-763
37. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-583
38. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
39. Melichar B, Koralewski B, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470-1476
40. Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007; 14: 2367-2376
41. Von Mos R, Seifert B, Ochsenbein A, et al. Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). ECCO-ESMO 2009; Abstract 24LBA.
42. O'Day SJ, Kim GP, Sosman JA, et al. BEAM: A randomized phase II study evaluating the activity of bevacizumab In combination with carboplatin plus paklitaxel In patients with previously untreated Advanced Melanoma. ECCO-ESMO 2009; Abstract 23LBA.
43. Boasberg P, Cruickshank S, Hamid O, O'Day S, Weber R, Spitler L. Nab-paclitaxel (Abraxane) and bevacizumab as first line therapy in patients with unresectable stage III nad IV melanoma. J Clin Oncol 2009; 27. Abstract 9061.
44. Peyton JD, Spigel DR, Burris HA, Lane C, Rubin M, Browning M, Trent D, Hainsworth JD. Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: Preliminary results. J Clin Oncol 2009; 27. Abstract 9027
45. Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A. Recent developments in renal cell cancer immunotherapy. Expert Opin Biol Ther 2007; 7: 727-737
46. Hersh EM, Weber JS, Powderly JD, et al. Disease control and long term survival in chemotherapy-naïve patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazin. 2008 ASCO Annual proceeding Part I. J Clin Oncol 2008; 26: Abstract 9022.
47. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053
48. Downey SG, Klaper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-6688
49. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolotis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289
50. Hamid O, Chin K, Li J, et al. Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study. 2008 ASCO Annual proceeding Part I. J Clin Oncol 2008; 26: Abstract 9025.
51. O'Day S, Weber J, Lebbe M. Effect of ipilimumuab treated on 18- month survival: Update of patient (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 2009; 27. Abstract 9033.
52. O'Day SJ, Ibrahim R, DePril V, et al. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. J Clin Oncol 2008; 26: Abstract 9021
53. http://clinicaltrial.gov/ct2/results?term=ipilimumab
54. Kirkwod JM, Lorigan P, Hersey P, et al. A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. 2008 ASCO Annual proceedings Part 1. J Clin Oncol 2008; 26: Abstract 9023.
55. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. 2008 ASCO Annual proceedings Part 1. J Clin Oncol 2008; 26: Abstract LBA9011.
56. Tarhini AA, Moschos SS, Schlesselman JJ, et al. Phase II trial combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or IV melanoma. 2008 ASCO Annual proceedings Part 1. J Clin Oncol 2008; 26: Abstract 9009.
57. Brahmer JR, Topalian S, Wollner I, et al. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol 2008; 26: 3006.
58. Sznol M, Hodi FS, Margolin K. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). 2008 ASCO Annual proceedings. J Clin Oncol 2008; 26. Abstract 3007.
59. http://www.clinicaltrial.gov/ct2/show/NCT00612664?term=4-1BB&rank=1.
60. Vonderheide RH, Flaherty K, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25: 876-883
61. NIH. Information on Clinical Trials and Human Research. US National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT0060 7048?term=CP-870%2C893&rank=1NIH
62. v integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004; 110: 326-335
63. v-integrin monoclonal antibody Intetumumab (CNTO 95) alone and in combination with dacarbazin in patients with stage IV melanoma: 12 month results. J Clin Oncol ASCO 2009; Abstract 9029.
64. Linette G, Cranmer L, Hodi S, et al. A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma. 2008 ASCO Annual proceeding Part I. J Clin Oncol 2008; 26. Abstract 3505.
65. Tse KF, Jeffers M, Pollack VA, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006; 12: 1373-1382
66. Hwu P, Sznol M, Pavlick A. A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (DC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma. J Clin Oncol 2009; 27. Abstract 9032.
67. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22: 3138-3151
68. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-4745
69. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980; 283: 593-596
70. Staibano S, Pepe S, Lo Muzio L, et al. Poly(adenosine diphosphateribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 2005; 36: 724-731
71. Plummer ER, Middleton M, Wilson R, et al. First in human Phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumor. J Clin Oncol 2005; 23. Abstract 208S.
72. Plummer ER, Lorigan P, Evans J, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 2006; 24. Abstract 456s.